TDP-43 toxicity in yeast.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Methods

• Publication date

  2011-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ymeth.2010.11.006PMID 21115123PMCID PMC3073690
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• TAR DNA-binding protein 43 in neurodegenerative disease

  2010cited by this paper
• Preventing Parkinson’s pathology

  2010cited by this paper
• Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS

  2010cited by this paper
• α-Synuclein Delays Endoplasmic Reticulum (ER)-to-Golgi Transport in Mammalian Cells by Antagonizing ER/Golgi SNAREs

  2010cited by this paper
• Cytoplasmic Mislocalization of TDP-43 Is Toxic to Neurons and Enhanced by a Mutation Associated with Familial Amyotrophic Lateral Sclerosis

  2010cited by this paper
• Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson’s disease models

  2010cited by this paper
• The Genetic Landscape of a Cell

  2010cited by this paper
• α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity

  2009cited by this paper
• Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis.

  2009cited by this paper
• Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity

  2009cited by this paper
• Impaired ERAD and ER stress are early and specific events in polyglutamine toxicity.

  2008cited by this paper
• TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis.

  2008cited by this paper
• Yeast

  2008cited by this paper
• Disturbance of Nuclear and Cytoplasmic TAR DNA-binding Protein (TDP-43) Induces Disease-like Redistribution, Sequestration, and Aggregate Formation*

  2008cited by this paper
• A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity

  2008cited by this paper
• TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis

  2008cited by this paper
• Novel Mutations in TARDBP (TDP-43) in Patients with Familial Amyotrophic Lateral Sclerosis

  2008cited by this paper
• TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis

  2008cited by this paper
• The Parkinson's disease protein α-synuclein disrupts cellular Rab homeostasis

  2008cited by this paper
• The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis.

  2008cited by this paper
• Structural determinants of the cellular localization and shuttling of TDP-43

  2008cited by this paper
• A suite of Gateway® cloning vectors for high‐throughput genetic analysis in Saccharomyces cerevisiae

  2007cited by this paper
• Beer and Bread to Brains and Beyond: Can Yeast Cells Teach Us about Neurodegenerative Disease?

  2007cited by this paper
• Approaching a complete repository of sequence-verified protein-encoding clones for Saccharomyces cerevisiae.

  2007cited by this paper
• Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis

  2006cited by this paper
• The Short N-terminal Domains of STIM1 and STIM2 Control the Activation Kinetics of Orai1 Channels*

  2006cited by this paper
• α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models

  2006cited by this paper
• A strategy for extracting and analyzing large-scale quantitative epistatic interaction data

  2006cited by this paper
• A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease

  2005cited by this paper
• Exploration of the function and organization of the yeast early secretory pathway through an epistatic miniarray profile.

  2005cited by this paper
• Exploration of essential gene functions via titratable promoter alleles.

  2004cited by this paper
• Alpha-synuclein locus duplication as a cause of familial Parkinson's disease.

  2004cited by this paper
• α-synuclein locus duplication as a cause of familial Parkinson's disease

  2004cited by this paper
• Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs

  2004cited by this paper
• Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease

  2004cited by this paper
• Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease.

  2004cited by this paper
• alpha-Synuclein locus triplication causes Parkinson's disease.

  2003cited by this paper
• Yeast Cells Provide Insight into Alpha-Synuclein Biology and Pathobiology

  2003cited by this paper
• Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores.

  2003cited by this paper
• α-Synuclein Locus Triplication Causes Parkinson's Disease

  2003cited by this paper
• Yeast Genes That Enhance the Toxicity of a Mutant Huntingtin Fragment or α-Synuclein

  2003cited by this paper
• Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein.

  2003cited by this paper
• NOBEL LECTURE: Yeast and Cancer

  2002cited by this paper
• Systematic screen for human disease genes in yeast

  2002cited by this paper
• The Nobel Prize and beyond

  2002cited by this paper
• Systematic Genetic Analysis with Ordered Arrays of Yeast Deletion Mutants

  2001cited by this paper
• Principles for the Buffering of Genetic Variation

  2001cited by this paper
• Principles for the buffering of genetic variation.

  2001cited by this paper
• Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.

  2000cited by this paper
• Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils.

  2000cited by this paper
• Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins.

  2000cited by this paper
• Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease

  1998cited by this paper
• α-Synuclein in Lewy bodies

  1997cited by this paper
• Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.

  1997cited by this paper
• Alpha-synuclein in Lewy bodies.

  1997cited by this paper
• Synthetic enhancement in gene interaction: a genetic tool come of age.

  1993cited by this paper
• A68: a major subunit of paired helical filaments and derivatized forms of normal Tau.

  1991cited by this paper
• Suppressors of yeast actin mutations.

  1989cited by this paper
• Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

  1984cited by this paper
• Transformation of intact yeast cells treated with alkali cations.

  1984cited by this paper
• A protease-resistant protein is a structural component of the scrapie prion.

  1983cited by this paper
• Transformation of intact yeast cells treated with alkali cations

  1983cited by this paper
• Early stages in the yeast secretory pathway are required for transport of carboxypeptidase Y to the vacuole.

  1982cited by this paper
• Genetics

  1981cited by this paper
• Order of events in the yeast secretory pathway.

  1981cited by this paper
• Identification of 23 complementation groups required for post-translational events in the yeast secretory pathway.

  1980cited by this paper
• The teaching of social and community medicine. Letting students do the work: an aspect of audiovisual aids to teaching.

  1970cited by this paper

• The effect of G-quadruplexes on TDP43 condensation, distribution, and toxicity

  2025cites this paper
• Deletion of the Saccharomyces cerevisiae RACK1 homolog, ASC1, enhances autophagy which mitigates TDP-43 toxicity

  2025cites this paper
• An adenine model of inborn metabolism errors alters TDP-43 aggregation and reduces its toxicity in yeast revealing insights into protein misfolding diseases

  2025cites this paper
• Myopathic aggregation-prone variants in the TDP-43 prion-like domain: genetics paving the way.

  2025cites this paper
• A Twist in Yeast: New Perspectives for Studying TDP-43 Proteinopathies in S. cerevisiae

  2025cites this paper
• Deciphering the interactome of Ataxin-2 and TDP-43 in iPSC-derived neurons for potential ALS targets

  2024cites this paper
• Expression of Wild-Type and Mutant Human TDP-43 in Yeast Inhibits TOROID (TORC1 Organized in Inhibited Domain) Formation and Autophagy Proportionally to the Levels of TDP-43 Toxicity

  2024cites this paper
• Drug Screening and Validation Targeting TDP-43 Proteinopathy for Amyotrophic Lateral Sclerosis

  2024cites this paper
• Structural Integrity of Nucleolin Is Required to Suppress TDP-43-Mediated Cytotoxicity in Yeast and Human Cell Models

  2023cites this paper
• Progress in biophysics and molecular biology proteostasis impairment and ALS.

  2022cites this paper
• Genome-wide CRISPR screen reveals v-ATPase as a drug target to lower levels of ALS protein ataxin-2

  2022cites this paper
• TDP-43 Toxicity in Yeast Is Associated with a Reduction in Autophagy, and Deletions of TIP41 and PBP1 Counteract These Effects

  2022cites this paper
• Elevated constitutive expression of Hsp40 chaperone Sis1 reduces TDP-43 aggregation-induced oxidative stress in Ire1 pathway dependent-manner in yeast TDP-43 proteinopathy model of amyotrophic lateral sclerosis.

  2022cites this paper
• Nearly 30 Years of Animal Models to Study Amyotrophic Lateral Sclerosis: A Historical Overview and Future Perspectives

  2021cites this paper
• Small molecule v-ATPase inhibitor Etidronate lowers levels of ALS protein ataxin-2

  2021cites this paper
• A yeast model of the ALS protein Matrin3 uncovers Hsp90 and its co-chaperone Sti1 as modifiers of misfolding and toxicity

  2021cites this paper
• Stress Granule Assembly Can Facilitate but Is Not Required for TDP-43 Cytoplasmic Aggregation

  2020cites this paper
• Opportunities and challenges in phenotypic screening for neurodegenerative disease research.

  2020cites this paper
• Comparative analysis of the intracellular responses to disease-related aggregation-prone proteins.

  2020cites this paper
• Hsp90 and its co-chaperone Sti1 control TDP-43 misfolding and toxicity

  2020cites this paper
• Tumor suppressor protein p53 expressed in yeast can remain diffuse, form a prion, or form unstable liquid-like droplets

  2020cites this paper
• Role of CNC1 gene in TDP-43 aggregation-induced oxidative stress-mediated cell death in S. cerevisiae model of ALS

  2020cites this paper
• Nucleolin Rescues TDP-43 Toxicity in Yeast and Human Cell Models

  2020cites this paper
• Yeast Models for the Study of Amyloid-Associated Disorders and Development of Future Therapy

  2019influential citation
• The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight?

  2019cites this paper
• ALS Yeast Models—Past Success Stories and New Opportunities

  2018cites this paper
• RNA-binding proteins in neurodegeneration: mechanisms in aggregate

  2017cites this paper
• Metal dependence and branched RNA cocrystal structures of the RNA lariat debranching enzyme Dbr1

  2016cites this paper
• An acridine derivative, [4,5-bis{(N-carboxy methyl imidazolium)methyl}acridine] dibromide, shows anti-TDP-43 aggregation effect in ALS disease models

  2016cites this paper
• PABPN1 suppresses TDP-43 toxicity in ALS disease models.

  2015cites this paper
• Approaches to study yeast cell aging and death.

  2014cites this paper
• Isolating potentiated Hsp104 variants using yeast proteinopathy models.

  2014cites this paper
• Therapeutic modulation of eIF2α-phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models

  2013cites this paper
• Nuclear TAR DNA-binding protein 43: A new target for amyotrophic lateral sclerosis treatment

  2013cites this paper
• Oxidative stress and neurodegeneration: the yeast model system.

  2013cites this paper
• Harnessing the power of yeast to unravel the molecular basis of neurodegeneration

  2013cites this paper
• Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models

  2012cites this paper
• New therapeutic strategies for cancer and neurodegeneration emerging from yeast cell-based systems.

  2012cites this paper
• The ALS disease protein TDP-43 is actively transported in motor neuron axons and regulates axon outgrowth.

  2012cites this paper
• RNA-Binding Proteins in Amyotrophic Lateral Sclerosis and Neurodegeneration

  2012cites this paper
• Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models

  2012cites this paper
• Mitochondrion-mediated cell death: dissecting yeast apoptosis for a better understanding of neurodegeneration

  2012cites this paper
• Yeast as a Model for Studying A Aggregation, Toxicity and Clearance

  2011cites this paper
• Neurotoxic 43-kDa TAR DNA-binding Protein (TDP-43) Triggers Mitochondrion-dependent Programmed Cell Death in Yeast

  2011cites this paper